scispace - formally typeset
R

Richard J. Ulevitch

Researcher at Scripps Research Institute

Publications -  240
Citations -  50508

Richard J. Ulevitch is an academic researcher from Scripps Research Institute. The author has contributed to research in topics: Innate immune system & CD14. The author has an hindex of 102, co-authored 239 publications receiving 49181 citations. Previous affiliations of Richard J. Ulevitch include French Institute of Health and Medical Research & University of Pennsylvania.

Papers
More filters
Journal ArticleDOI

CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.

TL;DR: CD14, a differentiation antigen of monocytes, was found to bind complexes of LPS and LBP, and blockade of CD14 with monoclonal antibodies prevented synthesis of TNF-alpha by whole blood incubated with LPS.
Journal ArticleDOI

Toll-like receptors in the induction of the innate immune response

TL;DR: A group of proteins that comprise the Toll or Toll-like family of receptors perform this role in vertebrate and invertebrate organisms and it is therefore not surprising that studies of the mechanism by which they act has revealed new and important insights into host defence.
Journal ArticleDOI

A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells

TL;DR: Findings link a signaling pathway in mammalian cells with a pathway in yeast that is responsive to physiological stress.
Journal ArticleDOI

Pro-inflammatory Cytokines and Environmental Stress Cause p38 Mitogen-activated Protein Kinase Activation by Dual Phosphorylation on Tyrosine and Threonine (∗)

TL;DR: It is demonstrated that p38, like JNK, is activated by treatment of cells with pro-inflammatory cytokines and environmental stress and the mechanism of p38 activation is mediated by dual phosphorylation on Thr-180 and Tyr-182.
Journal ArticleDOI

Structure and function of lipopolysaccharide binding protein

TL;DR: The identification of this pathway for LPS-induced monocyte stimulation may aid in the development of treatments for diseases in which Gram-negative sepsis or endotoxemia are involved.